HSPA6 and central nervous system cancer: To further investigate the mechanisms undergoing how HSPA6 may be associated with the outcome of patients with glioma, we identified DEGs by comparing subgroups with low and high expression levels of HSPA6 in the three cohorts (FDR <0.05 and log2Fold Change >1) using the Wilcoxon rank sum test.